NCT05383131View on ClinicalTrials.gov

To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 23, 2021

Primary Completion Date

November 30, 2021

Study Completion Date

November 30, 2021

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

HEC585

Mulltiple doses of HEC585 for up to 10 days

DRUG

Pirfenidone

Mulltiple doses of Pirfenidone for up to 3 days

DRUG

Nintedanib

Mulltiple doses of Nintedanib for up to 7 days

Trial Locations (1)

Unknown

Shanghai Xuhui Central Hospital, Shanghai

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY